Malaria treatment: Eli Lilly announces discontinuation of IV quinidine
by News Desk from Outbreak News Today on (#3B41F)
Earlier this month, pharmaceutical manufacturer, Eli Lilly announced that it will no longer be producing IV quinidine gluconate, but plans to continue distributing the product until the current stock expires (March 2019). As of today, intravenous quinidine gluconate remains available for the treatment of severe malaria. CDC and FDA are developing a strategy to ensure continued ["]
The post Malaria treatment: Eli Lilly announces discontinuation of IV quinidine appeared first on Outbreak News Today.